Cynosure Lutronic and Amico Aesthetics Join Forces by Signing a Strategic Distribution Agreement for the Middle East
Cynosure Lutronic, a global leader in the energy-based devices market, has entered into a multi- country distribution agreement with Amico Aesthetics, a leader in providing world-class medical devices to the Middle East.
Effective January 1, 2025, Amico Aesthetics has become the sole authorized distributor of the whole Cynosure Lutronic portfolio across its entire network in the Middle East including UAE, KSA, Kuwait, Qatar, Jordan, Iraq, Egypt, Bahrain, Oman and Lebanon. This strategic relationship further strengthens both companies’ presence and commitment to customer excellence in the region's energy-based device industry.
A Leading-Edge Alliance
This alliance unites Cynosure Lutronic’s innovative technologies with Amico Aesthetics’ robust distribution network and localized expertise, creating a powerful synergy aimed at delivering unparalleled value to aesthetic practitioners and their patients. Together, both companies aim to elevate aesthetic practice standards and results across the Middle East.
Ahmed El-Maghraby, CEO of Amico Group, shared his enthusiasm: “We are delighted to expand our collaboration with Cynosure Lutronic, a company that shares our commitment to excellence and innovation. Cynosure Lutronic combines a legacy of premium quality with a reputation for groundbreaking advancements, a combination that perfectly matches our mission to provide aesthetic professionals with best-in-class technologies.
Our comprehensive support programs, new training centers, and a team of over 250 dedicated specialists will ensure exceptional aesthetic outcomes for both practitioners and their patients. We look forward to continuing our successful collaborations and supporting customers across the Middle East.”
Nadav Tomer, CEO of Cynosure Lutronic, added: “Amico’s reputation and their deep understanding of the Middle East markets make them an ideal partner for us. This agreement marks a significant step forward in expanding Cynosure Lutronic’s footprint and delivering our cutting-edge solutions to aesthetic professionals in the region. We remain committed to providing exceptional support and innovation to our customers.”
Shaping the Future of Aesthetic Medicine
The collaboration between Cynosure Lutronic and Amico Aesthetics will prioritize delivering tailored clinical training, dedicated consumer marketing, and exceptional customer service. By combining their expertise, both companies aim to seamlessly integrate Cynosure Lutronic’s state-of-the-art product portfolio into the Middle East region, setting new benchmarks for aesthetic outcomes.
For additional information and questions, please click on the following links:
- For Cynosure Lutronic: https://www.cynosurelutronicemea.com/contact-us/
- For Amico Aesthetics: https://www.amicogroup.com/contacts/
About Amico:
Amico is a leading medical device distributor specializing in bringing advanced healthcare solutions to the Middle East. With decades of experience, Amico is dedicated to improving patient care through its extensive portfolio of innovative products and services.
About Cynosure Lutronic:
With over 30 years of combined innovation and action as the global leader in energy-based devices and superior medical aesthetic treatments. Cynosure Lutronic enables dermatologists, plastic surgeons, medical spas, and other healthcare practitioners to deliver non-invasive and minimally invasive procedures to their patients. Committed to research and development at the forefront of aesthetic technology, Cynosure Lutronic holds the largest market leading portfolio of products in skin resurfacing and revitalization, hair removal, vascular lesion treatment, skin toning, and body contouring. Cynosure Lutronic sells its products globally through a direct sales force in the United States, Canada, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, and through international distributors in approximately 130 other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227795251/en/
Contacts
PR Contact:
Nikhil Nathwani
nikhil.nathwani@cynosurelutronic.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom